Adamas Announces New Employment Inducement Grant
December 08 2017 - 4:05PM
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the
compensation committee of the company’s board of directors granted
64 new employees the option to purchase an aggregate of 77,550
shares of the company’s common stock, at a per share exercise price
of $35.76, the closing trading price on December 7, 2017, and
restricted stock units to acquire 38,775 shares of the company’s
common stock. The stock option and restricted stock units vest over
four years and were granted pursuant to the Adamas Pharmaceuticals,
Inc. 2016 Inducement Plan, which was approved by the company's
board of directors in March 2016 under Rule 5653(c)(4) of the
Nasdaq Global Market for equity grants to induce new employees to
enter into employment with the company.
About Adamas Pharmaceuticals,
Inc.At Adamas, we believe in the power and the promise of
medicines derived from a deep understanding of time-dependent
biology. Our expertise lies in uncovering and mapping the
relationship between disease and drug activity. From there, we
strive to create medicines with therapeutic profiles that match the
pattern of disease to drive a more significant and durable clinical
effect. This understanding of time-dependent biological processes
informs our every innovation, targeting advancement in treatment of
chronic neurologic disorders. Our portfolio includes: GOCOVRITM
(amantadine) extended release capsules (previously ADS-5102), the
first and only FDA-approved medicine for the treatment of
dyskinesia in patients with Parkinson’s disease receiving
levodopa-based therapy, with or without concomitant dopaminergic
medications; ADS-5102 in development for the treatment of multiple
sclerosis walking impairment; and ADS-4101, a high-dose,
modified-release lacosamide in Phase 1 clinical development for the
treatment of partial onset seizures in patients with epilepsy. For
more information, please visit www.adamaspharma.com.
Contact:
Ashleigh Barreto
Director, Corporate Communications & Investor Relations
Adamas Pharmaceuticals, Inc.
510-450-3567
ir@adamaspharma.com
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Sep 2023 to Sep 2024